Literature DB >> 28292498

Treacle and Smallpox: Two Tests for Multicriteria Decision Analysis Models in Health Technology Assessment.

Alec Morton1.   

Abstract

Multicriteria decision analysis (MCDA) is rightly receiving increasing attention in health technology assessment. Nevertheless, a distinguishing feature of the health domain is that technologies must actually improve health, and good performance on other criteria cannot compensate for failure to do so. We argue for two reasonable tests for MCDA models: the treacle test (can a winning intervention be incompletely ineffective?) and the smallpox test (can a winning intervention be for a disease that no one suffers from?). We explore why models might fail such tests (as the models of some existing published studies would do) and offer some suggestions as to how practice should be improved.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  decision analysis; health technology assessment; multicriteria decision analysis; preferential independence

Mesh:

Year:  2016        PMID: 28292498     DOI: 10.1016/j.jval.2016.10.005

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  6 in total

1.  A novel measure of drug benefit-risk assessment based on Scale Loss Score.

Authors:  Gaelle Saint-Hilary; Veronique Robert; Mauro Gasparini; Thomas Jaki; Pavel Mozgunov
Journal:  Stat Methods Med Res       Date:  2018-07-20       Impact factor: 3.021

2.  A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit-risk assessment.

Authors:  Tom Menzies; Gaelle Saint-Hilary; Pavel Mozgunov
Journal:  Stat Methods Med Res       Date:  2022-01-19       Impact factor: 3.021

3.  Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden.

Authors:  Aris Angelis
Journal:  MDM Policy Pract       Date:  2018-09-15

4.  Enhancing the Value of the ASCO Value Framework.

Authors:  Alec Morton; Peter B Bach; Andrew Briggs
Journal:  MDM Policy Pract       Date:  2018-05-29

5.  Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis.

Authors:  Aris Angelis; Mark Thursz; Vlad Ratziu; Alastair O'Brien; Lawrence Serfaty; Ali Canbay; Ingolf Schiefke; Joao Bana E Costa; Pascal Lecomte; Panos Kanavos
Journal:  Med Decis Making       Date:  2020-08       Impact factor: 2.583

Review 6.  Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings.

Authors:  Kevin Marsh; Praveen Thokala; Sitaporn Youngkong; Kalipso Chalkidou
Journal:  Cost Eff Resour Alloc       Date:  2018-11-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.